Register for Webinar

Webinar

How veterinarians are using liquid biopsy for cancer detection in dogs: a look at clinical performance and real-world results

Once a test has been validated and is commercially available, it is important for the laboratory to periodically report utilization and performance metrics regarding the test. Blood-based liquid biopsy using next-generation sequencing became clinically available in May 2021. Since that time, the test has been ordered for thousands of patients, primarily as a screening tool for dogs at higher risk of cancer, and as an aid in diagnosis for dogs for which there is a clinical suspicion of cancer. This session will review data from a cohort of 1,500 consecutive liquid biopsy tests received for commercial testing at one clinical laboratory, and will include a discussion of ordering patterns, positivity rates, and patient outcome data, along with how this data can be used to discuss liquid biopsy testing with clients. A series of interesting case studies will be presented, exploring the use of this testing in a variety of clinical settings.

This program has been approved for 1 hour of continuing education credit in jurisdictions that recognize RACE approval.

Speaker

Allison O’Kell

DVM, MS, DACVIM (SAIM)
PetDx Director of Clinical Support

Register for Webinar